Cargando…
Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis
BACKGROUND: Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central nervous system and is one of the leading causes of disability in young adults. Cell therapy is emerging as a therapeutic strategy to promote repair and regeneration in patients with disability associated w...
Autores principales: | Harris, Violaine K., Stark, James, Vyshkina, Tamara, Blackshear, Leslie, Joo, Gloria, Stefanova, Valentina, Sara, Gabriel, Sadiq, Saud A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5925446/ https://www.ncbi.nlm.nih.gov/pubmed/29449193 http://dx.doi.org/10.1016/j.ebiom.2018.02.002 |
Ejemplares similares
-
Mesenchymal stem cell-neural progenitors are enriched in cell signaling molecules implicated in their therapeutic effect in multiple sclerosis
por: Harris, Violaine K., et al.
Publicado: (2023) -
Mesenchymal stem cell-derived neural progenitors in progressive MS: Two-year follow-up of a phase I study
por: Harris, Violaine K., et al.
Publicado: (2020) -
Biomarkers of Therapeutic Response in Multiple Sclerosis: Current Status
por: Harris, Violaine K., et al.
Publicado: (2014) -
Biomarkers of multiple sclerosis: current findings
por: Harris, Violaine K, et al.
Publicado: (2017) -
Safety of long-term intrathecal methotrexate in progressive forms of
MS
por: Stark, James W., et al.
Publicado: (2019)